Full Spectrum Diligence is Key to Biotech Funding
At this year’s BIO Convention in Boston, Ali Pashazadeh, Treehill Partners CEO, spoke with Manasee Kurlekar, BioSpectrum Asia Chief Executive Officer, about the urgent and existential need in the biotech industry to broaden their capabilities beyond the molecule towards a fully integrated skillset along the value chain.
“The science may spark initial interest, but funding decisions are made after evaluating the CRO network, manufacturing readiness, clinical protocol viability, target product profile, and the management team’s capacity to deliver.”
Read the article on BioSpectrum: